comparemela.com

Latest Breaking News On - Hong kong stock exchange 1877 hk - Page 1 : comparemela.com

Junshi Biosciences Announces NDA Acceptance in Hong Kong

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading.

United statesUnited kingdomSan franciscoHong kong special administrative regionHong kong generalHong kongSouth africaZhi liJunshi biosciencesAmerican society of clinical oncologyNational reimbursement drug listDrug officeDepartment of healthIr teamEuropean unionAustralia therapeutic goods administration

Junshi Biosciences Announces 2023 Full Year Financial

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading.

New zealandUnited kingdomSouth africaSan franciscoUnited statesRepublic ofZhi liJunshi bioscienceJunshi biosciencesTherapeutic goods administrationNational medical products administration of chinaIr teamShanghai junshi biosciences co ltdAustralian government department of healthRegulatory agencyPr team

Junshi Biosciences Announces Toripalimab s NDA Accepted by

SHANGHAI, China, Feb. 01, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading.

San franciscoUnited statesUnited kingdomZhi liJunshi biosciencesDrug administrationOncology centerRegulatory agencyJournal of the american medical associationEuropean unionWorld health organizationPr teamShanghai junshi biosciences co ltdAustralia therapeutic goods administrationAmerican society of clinical oncologyHealth canada

Junshi Biosciences Announces Lancet Infectious Diseases

SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading.

United statesYun lingZhi liJunshi biosciencesXinjiang technical institute of physicsWuhan institute of virologyCentral asian centerShanghai junshi biosciences co ltdShanghai public health clinical centerGlobal researchShanghai institute of materia medicaDevelopment chinese academy of sciences chinaIr teamVigonvita life sciences co ltdPr teamLingang laboratory

Junshi Biosciences Announces Acceptance of the Supplemental

SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading.

United statesSan franciscoYing chengUnited kingdomZhi liJunshi biosciencesJunshi bioscienceEuropean medicines agencyChinese society of clinical oncologyRegulatory agencyIr teamShanghai junshi biosciences co ltdDrug administrationGlobal researchNational reimbursement drug listPr team

vimarsana © 2020. All Rights Reserved.